@article{103522,
  keywords = {Metabolism, Clofazimine, Leprosy patients},
  author = {Feng P and Fenselau C and Jacobson R},
  title = {Metabolism of clofazimine in leprosy patients.},
  abstract = {<p>We have identified two metabolites of clofazimine (B663; Lamprene; 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-isopropyliminophenazine) in our initial investigation of its metabolism in leprosy patients. Based on mass, ultraviolet, and visible spectrometry, we characterized an unconjugated (metabolite I, 3-(p-hydroxyanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-isopropyliminophenazine ) and a conjugated (metabolite II, 3-(beta-D-glucopyranosiduronic acid)-10-(p-chlorophenyl)-2,10-dihydro-2-isopropyliminophenazine) metabolite from the urine of patients. Both metabolites were red in color, similar to clofazimine; however, both were considerably more polar than the parent drug. We suggest that metabolite I was formed by a hydrolytic dehalogenation reaction, and metabolite II by hydrolytic deamination followed by glucuronidation.</p>},
  year = {1981},
  journal = {Drug metabolism and disposition: the biological fate of chemicals},
  volume = {9},
  pages = {521 - 524},
  month = {01/1981},
  issn = {0090-9556},
  language = {ENG},
}